These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 31873726

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU, Talluri S, Riaz H, Rahman H, Nasir F, Bin Riaz I, Sattur S, Ahmed H, Kaluski E, Krasuski R.
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study.
    Blom DJ, Ranjith N, Joshi P, Naidoo P, van Tonder A, Musa MG, Joshi S, Leisegang R, Trokis JS, Makan H, Raal FJ.
    Cardiovasc J Afr; 2020 May; 31(5):245-251. PubMed ID: 33151240
    [Abstract] [Full Text] [Related]

  • 5. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N, Tocci G, Ferri C.
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?
    Reklou A, Katsiki N, Karagiannis A, Athyros V.
    Curr Vasc Pharmacol; 2020 Mar; 18(1):38-42. PubMed ID: 30663570
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
    De Ferrari GM, Perna GP, Nicosia A, Guasti L, Casu G, Cuccia C, Picco F, Strazzella C, Totaro R, Cercone S, Canullo L, Horack M, Lautsch D, Gitt AK, Di Biase M.
    J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
    [Abstract] [Full Text] [Related]

  • 14. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP.
    Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

  • 18. LDL cholesterol: How low to go?
    Packard CJ.
    Trends Cardiovasc Med; 2018 Jul; 28(5):348-354. PubMed ID: 29336946
    [Abstract] [Full Text] [Related]

  • 19. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
    Zafrir B, Jubran A.
    Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
    [Abstract] [Full Text] [Related]

  • 20. Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk.
    Ingueneau C, Hollstein T, Grenkowitz T, Ruidavets JB, Kassner U, Duparc T, Combes G, Perret B, Genoux A, Schumann F, Bobbert T, Steinhagen-Thiessen E, Martinez LO.
    Vascul Pharmacol; 2020 Dec; 135():106804. PubMed ID: 32987194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.